Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Celsion (CLSN – Research Report), Aileron Therapeutics (ALRN – Research Report) and Monopar Therapeutics Inc (MNPR – Research Report).
Celsion (CLSN)
In a report released today, Emily Bodnar from H.C. Wainwright maintained a Buy rating on Celsion, with a price target of $16.00. The company’s shares closed last Monday at $2.54, close to its 52-week low of $1.80.
According to TipRanks.com, Bodnar is a 4-star analyst with an average return of
Celsion has an analyst consensus of Moderate Buy, with a price target consensus of $16.00.
See today’s best-performing stocks on TipRanks >>
Aileron Therapeutics (ALRN)
H.C. Wainwright analyst Edward White initiated coverage with a Hold rating on Aileron Therapeutics today. The company’s shares closed last Monday at $0.21, close to its 52-week low of $0.13.
According to TipRanks.com, White has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
The word on The Street in general, suggests a Hold analyst consensus rating for Aileron Therapeutics.
Monopar Therapeutics Inc (MNPR)
In a report released today, Sean Lee CFA from H.C. Wainwright maintained a Buy rating on Monopar Therapeutics Inc, with a price target of $6.00. The company’s shares closed last Monday at $1.85, close to its 52-week low of $1.70.
According to TipRanks.com, CFA ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
Monopar Therapeutics Inc has an analyst consensus of Strong Buy, with a price target consensus of $8.67, implying a 327.1% upside from current levels. In a report issued on August 11, JonesTrading also maintained a Buy rating on the stock with a $15.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on CLSN:
- Buckreef Gold’s Main Zone Extended And Chased Toward The Surface
- H.C. Wainwright Sticks to Their Buy Rating for Biora Therapeutics (BIOR)
- Positive Report for Diffusion Pharmaceuticals (DFFN) from H.C. Wainwright
- H.C. Wainwright Remains a Buy on TransCode Therapeutics (RNAZ)
- Anixa Biosciences (ANIX) Gets a Buy from H.C. Wainwright
